These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 16869051)

  • 21. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.
    Dayan CM; Wraith DC
    Clin Exp Immunol; 2008 Feb; 151(2):231-4. PubMed ID: 18190459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trials in Israel: some considerations.
    Dolev E
    Isr Med Assoc J; 2000 Jun; 2(6):478-9. PubMed ID: 10897244
    [No Abstract]   [Full Text] [Related]  

  • 24. Italy launches clinical trial for HIV vaccine.
    Nature; 2008 Jul; 454(7204):564. PubMed ID: 18668075
    [No Abstract]   [Full Text] [Related]  

  • 25. The sex kitten of bioethics? Research ethics comes of age.
    Dresser R
    Hastings Cent Rep; 2008; 38(5):5. PubMed ID: 18947127
    [No Abstract]   [Full Text] [Related]  

  • 26. In vivo pharmacology in drug discovery and development.
    Svendsen O; Ahnfelt-Rønne I; Vanhoutte P
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):89-90. PubMed ID: 16918707
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
    Assaf C; Sterry W
    Curr Opin Mol Ther; 2007 Apr; 9(2):197-203. PubMed ID: 17458175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translation of innovative designs into phase I trials.
    Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
    J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesenchymal stem cells for ALS patients.
    Mazzini L; Vercelli A; Mareschi K; Ferrero I; Testa L; Fagioli F
    Amyotroph Lateral Scler; 2009 Apr; 10(2):123-4. PubMed ID: 19085190
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 31. Establishment of phase I trials in Israel.
    Atsmon J; Gill TS; Radu P; Rabin C
    Isr Med Assoc J; 2000 Jun; 2(6):417-20. PubMed ID: 10897229
    [No Abstract]   [Full Text] [Related]  

  • 32. Critically ill men in drug trial continue to improve.
    Mayor S
    BMJ; 2006 Apr; 332(7544):746. PubMed ID: 16575063
    [No Abstract]   [Full Text] [Related]  

  • 33. France releases interim report on drug trial disaster.
    Casassus B
    Lancet; 2016 Feb; 387(10019):634-635. PubMed ID: 26876704
    [No Abstract]   [Full Text] [Related]  

  • 34. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethical considerations in pediatric oncology phase I clinical trials according to The Belmont Report.
    Haylett WJ
    J Pediatr Oncol Nurs; 2009; 26(2):107-12. PubMed ID: 19190176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
    Abdel-Rahman SM; Reed MD; Wells TG; Kearns GL
    Clin Pharmacol Ther; 2007 Apr; 81(4):483-94. PubMed ID: 17329988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I drug combination trial design: walking the tightrope.
    Hamberg P; Verweij J
    J Clin Oncol; 2009 Sep; 27(27):4441-3. PubMed ID: 19704054
    [No Abstract]   [Full Text] [Related]  

  • 38. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trials may not need to be viewed as extraordinarily different from other clinical research.
    Sharma S
    J Clin Oncol; 2006 Oct; 24(28):e47. PubMed ID: 17008685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.